What is BioMarin Pharmaceuticals's market cap?

BioMarin Pharmaceuticals (BMRN) has a market capitalization of $12.0B and trades on NASDAQ.

What is BioMarin Pharmaceuticals's revenue and profitability?

BioMarin Pharmaceuticals generated $3.2B in trailing twelve-month revenue with net income of $501.0M, representing a net margin of 16.8%. Gross margin stands at 76.5%, with free cash flow of $767.1M. These figures are based on the Q1 2026 filing.

Who are BioMarin Pharmaceuticals's competitors?

BioMarin Pharmaceuticals's key competitors include BridgeBio Pharma, Inc., PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does BioMarin Pharmaceuticals partner with?

BioMarin Pharmaceuticals's notable partners include Sanofi.

What subsidiaries does BioMarin Pharmaceuticals have?

BioMarin Pharmaceuticals's subsidiaries include Inozyme Pharma, Inc., Amicus Therapeutics, Inc., BioMarin/Genzyme LLC.

Where is BioMarin Pharmaceuticals headquartered?

BioMarin Pharmaceuticals is headquartered in United States of America and employs approximately 3,401 people. It has been publicly traded since 1999.

BioMarin Pharmaceuticals

BMRN

BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the discovery, development, and commercialization of first-in-class therapies for rare genetic diseases.

Market cap

$12B+6.4%

Revenue$3.2B+9.9%

Net income$501.0M+17.4%

Free cash flow$767.1M+22.9%

EPS (diluted)$2.56+15.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$766.0MBeat by $13.5M EPS$0.55Miss by $0.39

Read the full report

Next report

Aug 3, 2026 (In 4 days)

Revenue estimate$932.0M

EPS estimate$0.96

Financials

Q1 2026

Income statement

See full

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Balance sheet

See full

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Cash flow

See full

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Free cash flow$199.7M+26.7%

Valuation & ratios

Valuation

See full

Market cap$12B+6.4%

Enterprise value$10.36B-1.9%

P/E24×—

P/S3.7×+0.1×

Profitability

See full

Gross margin76.5%-2.9pp

FCF margin23.7%+2.5pp

Returns & leverage

See full

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Segments

By product

See full

VOXZOGO$219.9M+2.9%

VIMIZIM$210.2M+11.6%

NAGLAZYME$130.1M+13.8%

PALYNZIQ$89.6M-4.0%

BRINEURA$47.1M+16.7%

By segment

See full

Reportable Segment$766.2M+2.8%

Competitors

By market cap

BridgeBio Pharma$16.8B+90.5%

BioMarin Pharmaceuticals$12.0B+7.4%

Crinetics Pharmaceuticals$8.9B+224%

PTC Therapeutics$6.3B+60.1%

MBX Biosciences, Inc.$2.9B+472%

Sarepta Therapeutics, Inc.$1.6B+4.7%

Solid Biosciences Inc.$784.6M+43.2%

Regenxbio$614.6M+45.0%

By revenue growth

Crinetics Pharmaceuticals+2,278%

BridgeBio Pharma+355%

BioMarin Pharmaceuticals+9.9%

Sarepta Therapeutics, Inc.+9.9%

Regenxbio-44.0%

PTC Therapeutics-53.3%

By net margin

PTC Therapeutics42.25%+119pp

BioMarin Pharmaceuticals16.82%+1.0pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

BridgeBio Pharma-125.85%+405pp

Regenxbio-330.23%-230pp

Solid Biosciences Inc.-1,062.28%—

Crinetics Pharmaceuticals-2,747.18%+40,444pp

Profile

BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the discovery, development, and commercialization of first-in-class therapies for rare genetic diseases. The company leverages genetic science to address the root causes of life-threatening conditions, maintaining a robust portfolio of commercial enzyme replacement therapies and a deep clinical pipeline targeting skeletal and metabolic disorders.

Competitive position

A leading global player in the rare disease space with a dominant position in enzyme replacement therapies and a first-mover advantage in achondroplasia treatments.

GeographiesUnited States, European Union, Japan, Brazil, Australia

Customer segmentsRare disease patients, Specialty pharmacies, Healthcare providers

Business modelResearch and Development, Manufacturing, Direct-to-provider sales

SuppliersSpecialized raw material suppliers, Contract manufacturing organizations (CMOs), Third-party logistics providers

CustomersSpecialty pharmacies, Hospitals, Government healthcare agencies, Pharmaceutical wholesalers

CountryUnited States of America

Listed1999

Employees3.4K

CEOAlexander Hardy

SectorHealthcare

IndustryBiotechnology

Websitebiomarin.com

FilingsSEC EDGAR

Ask your AI about BioMarin Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's market cap?: BioMarin Pharmaceuticals (BMRN) has a market capitalization of $12.0B and trades on NASDAQ.
What is BioMarin Pharmaceuticals's revenue and profitability?: BioMarin Pharmaceuticals generated $3.2B in trailing twelve-month revenue with net income of $501.0M, representing a net margin of 16.8%. Gross margin stands at 76.5%, with free cash flow of $767.1M. These figures are based on the Q1 2026 filing.
Who are BioMarin Pharmaceuticals's competitors?: BioMarin Pharmaceuticals's key competitors include BridgeBio Pharma, Inc., PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does BioMarin Pharmaceuticals partner with?: BioMarin Pharmaceuticals's notable partners include Sanofi.
What subsidiaries does BioMarin Pharmaceuticals have?: BioMarin Pharmaceuticals's subsidiaries include Inozyme Pharma, Inc., Amicus Therapeutics, Inc., BioMarin/Genzyme LLC.
Where is BioMarin Pharmaceuticals headquartered?: BioMarin Pharmaceuticals is headquartered in United States of America and employs approximately 3,401 people. It has been publicly traded since 1999.